Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study

Wang, Yan; Chen, Jianhua; Wu, Shengqi; Hu, Chenping; Li, Xiaoling; Wang, Yuqin; Yang, Yicheng; Rajan, Narayan; Chen, Yun; Chen, Yi; Luo, Zhuanzhuan; Chen, Wendong

doi:10.1186/1471-2407-14-940

Table 1 Patient baseline characteristics, selection of the platinum agent, and hematological AE management of studied doublets

From: Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study

Platinum-based doublet	Platinum/Pemetrexed			Platinum/Docetaxel			Platinum/Paclitaxel			Platinum/Gemcitabine			Platinum/Vinorelbine
Sample size	517			248			322			450			309			P value*
Variables	N	Mean/%	STDEV	N	Mean/%	STDEV	N	Mean/%	STDEV	N	Mean/%	STDEV	N	Mean/%	STDEV
Demography
Age (years)	511	55.5	9.8	248	54.1	9.9	322	53.8	10.5	447	55.1	9.4	308	53.5	10.2	*0.019*
BMI	441	23.6	3.2	136	23.9	3.2	214	23.5	3.3	332	23.7	3.3	103	23.0	3.4	0.228
BSA (m²)	457	1.7	0.2	214	1.7	0.2	276	1.7	0.2	395	1.7	0.2	266	1.6	0.2	*<0.001*
Male (%)	303	58.6%	—	166	66.9%	—	194	60.3%	—	296	65.8%	—	187	60.5%	—	0.074
Non-smoking (%)	291	56.3%	—	107	43.2%	—	173	53.7%	—	211	46.9%	—	159	51.5%	—	*0.003*
Public health insurance plan (%)
Urban residents	307	59.4%	—	132	53.2%	—	166	51.6%	—	231	51.3%	—	132	42.7%	—	*<0.001*
Rural residents	89	17.2%	—	65	26.2%	—	76	23.6%	—	108	24.0%	—	126	40.8%	—	*<0.001*
ECOG performance status (%)
0	193	37.3%	—	58	23.4%	—	128	39.8%	—	133	29.6%	—	60	19.4%	—	*<0.001*
1	304	58.8%	—	180	72.6%	—	190	59.0%	—	299	66.4%	—	237	76.7%	—	*<0.001*
2	13	2.5%	—	9	3.6%	—	3	0.9%	—	13	2.9%	—	10	3.2%	—	0.265
Baseline marrow function
Hemoglobin (g/l)	495	132.9	17.6	241	131.0	16.5	317	132.8	15.3	426	132.5	19.3	304	129.4	17.3	*0.043*
Neutrophilic granulocyte count ( ×10⁹/l)	491	5.2	2.4	239	4.9	2.2	318	5.2	2.3	422	5.2	2.6	304	4.9	2.0	0.112
WBC ( ×10⁹/l)	495	7.6	2.6	242	7.4	2.8	318	7.6	2.7	428	7.8	2.8	305	7.5	2.4	0.601
Platelet count ( ×10¹⁰/l)	493	24.9	8.0	241	25.6	9.4	317	25.9	8.6	424	25.0	25.8	304	24.8	8.2	0.213
Tumor stage and histology (%)
Stage 4	478	92.5%	—	215	86.7%	—	273	84.8%	—	395	87.8%	—	248	80.4%	—	*<0.001*
Adenocarcinoma type	512	99.0%	—	241	97.2%	—	313	97.2%	—	440	97.8%	—	307	99.3%	—	0.272
Number of metastasis site (%)
1	250	48.4%	—	107	43.2%	—	143	44.4%	—	100	22.2%	—	153	49.7%	—	0.513
2	123	23.8%	—	49	19.8%	—	70	21.7%	—	211	46.9%	—	66	21.2%	—	0.758
3 or above	64	12.4%	—	20	8.1%	—	32	9.9%	—	100	22.2%	—	22	7.2%	—	0.083
Location of metastasis (%)
Brain	84	16.3%	—	49	19.8%	—	58	18.0%	—	68	15.1%	—	42	13.7%	—	0.289
Bone	200	38.7%	—	87	35.1%	—	98	30.4%	—	162	36.0%	—	109	35.3%	—	0.199
Liver	48	9.3%	—	23	9.3%	—	29	9.0%	—	32	7.1%	—	24	7.8%	—	0.729
Pleural	128	24.8%	—	28	11.3%	—	50	15.5%	—	80	17.8%	—	45	14.7%	—	*<0.001*
Platinum agent used in doublet
Cisplatin	400	77.4%	—	111	44.7%	—	251	77.8%	—	385	85.6%	—	272	87.9%	—	*<0.001*
Carboplatin	117	22.6%	—	137	55.3%	—	71	22.2%	—	65	14.4%	—	37	12.1%	—	*<0.001*
Hematological AE management
G-CSF	172	33.3%	—	108	43.5%	—	167	51.9%	—	209	46.4%	—	215	69.6%	—	*<0.001*
EPO	5	1.0%	—	1	0.3%	—	0	0.0%	—	9	2.0%	—	3	1.0%	—	0.066
IL-11	16	3.1%	—	5	1.9%	—	3	0.9%	—	44	9.8%	—	39	12.6%	—	*<0.001*
TPO	17	3.3%	—	2	0.6%	—	0	0.0%	—	9	2.0%	—	3	1.0%	—	*0.003*
RBC	1	0.2%	—	0	0.0%	—	0	0.0%	—	5	1.1%	—	8	2.6%	—	*<0.001*
Platelet	1	0.2%	—	1	0.3%	—	0	0.0%	—	3	0.7%	—	4	1.3%	—	0.148

AE, adverse event; STDEV, standard deviation; BMI, body mass index; BSA, body surface area; ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell; G-CSF, granulocyte colony-stimulating factor; EPO, erythropoietin; IL-11, interleukin 11; TPO, thrombopoietin; RBC, red blood cell. *: P values less than 0.05 were in bold to indicate significant differences.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us